Work

Clinical validation of whole-genome and transcriptome sequencing for genetic diagnostics in adult and pediatric AML

Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Diagnosis and risk stratification of acute myeloid leukemia (AML) rely on the detection of diverse genetic aberrations using multiple standard-of-care (SoC) assays. With the increasing number of clinically relevant alterations and limited resolution of SoC methods, whole-genome and transcriptome sequencing (WGTS) represents a promising alternative. In this multi-center study, we evaluated the technical feasibility and clinical performance of WGTS across five sites in Sweden by comparison with SoC diagnostics. A total of 235 patients (197 adults and 38 children) underwent parallel SoC testing and WGTS analysis. WGTS identified 57/58 (98%) clinically relevant gene rearrangements detected by SoC and revealed an additional 12 rearrangements, including RUNX1 :: RUNX1T1 , KMT2A and NUP98 rearrangements. For structural variants and copy-number variants, WGS showed 90% concordance with SoC, with discrepancies mainly involving subclonal events or tetraploidy. For gene mutations, WGS achieved 94% sensitivity, detecting all NPM1, CEBPA bZIP, and IDH1/2 mutations, but missing low-frequency FLT3 -ITDs. Tumor-only analysis performed comparably to paired analysis for clinically relevant variants. Diagnostic classification was highly concordant between WGTS and SoC (WHO: 94%; ICC: 93%), with improved genetic subclassification in 5–6% of cases by WGTS. ELN risk stratification was concordant in 97% with WGTS reclassifying 2% of patients. Finally, a ring trial involving seven cases demonstrated complete agreement across sites in identifying aberrations. In conclusion, WGTS is a feasible and accurate comprehensive diagnostic approach for AML in a decentralized setting, improving detection of clinically relevant aberrations. However, complementary high-sensitivity assays for FLT3- ITD remain necessary for routine clinical implementation. Key points Whole-genome and transcriptome sequencing (WGTS) uncovers all clinically relevant variants in AML detected by standard-of-care (SoC) assays, with the exception of FLT3 -ITDs at low allele frequency, which require sensitive targeted assays. Compared with SoC assays, WGTS improves detection of clinically relevant gene rearrangements, resulting in a 5–6% increase in genetically based AML diagnoses. Nationwide multicenter validation demonstrates that WGTS can be implemented in a decentralized setting.
Source: medRxiv
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: green
OpenAlex ID: W7236442047
Cites: 31
Cited by:
Related to: 10